Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.61 which represents a slight increase of $1.69 or 14.18% from the prior close of $11.92. The stock opened at $11.87 and touched a ...

The Novavax vaccine, which was approved by the FDA at the end of August, is the only non-mRNA updated COVID vaccine that is ...

Doses of Moderna's updated COVID-19 vaccine are expected to begin arriving in Canada 'within days,' a spokesperson for the ...

Wayfair (W) stock price has remained under pressure in the past few years as concerns about weak consumer spending remain. It ...

Novavax Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -28.95% and a profit margin of -29.80%, with a gross margin of 154.25%. The ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...